Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Christian Agboton

United States

Research Interests

Explore related searches

Articles (30)

Collaborators (4)

Raja Atreya

University Hospital Erlangen

Alessandro Armuzzi

Humanitas University

Laurent Peyrin‐Biroulet

Shahnaz Khan

Health Solutions

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Christian Agboton

Research Interests

Explore related searches

Articles (30)

Collaborators (4)

Raja Atreya

Alessandro Armuzzi

Laurent Peyrin‐Biroulet

Shahnaz Khan

Make your next move.

Christian Agboton

Research Interests

Explore related searches

Articles (30)

A decade of clinical data with vedolizumab: the past, present, and future

Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn’s disease

S1771 Real-World Comparative Outcomes of Vedolizumab and Ustekinumab in Biologic-Naïve and Biologic-Experienced Patients With Crohn’s Disease in the United States and Canada

S1772 Real-World Effectiveness, Treatment Patterns, and Safety of Vedolizumab and Ustekinumab in Crohn’s Disease: A Retrospective Cohort Study in the United States and Canada

Mo1510 MOLECULAR AND CELLULAR SIGNATURES ACCOMPANYING EARLY DISEASE CLEARANCE IN ULCERATIVE COLITIS PATIENTS TREATED WITH VEDOLIZUMAB IN THE VERDICT TRIAL

Mo1517 EVALUATION OF TRANSMURAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE SHOWS EARLY EFFICACY OF VEDOLIZUMAB: VECTORS WEEK 14 INTERIM ANALYSIS

Tu1487 MOLECULAR CHARACTERIZATION OF RESPONDERS TO VEDOLIZUMAB IDENTIFIED BY SYMPTOM RESPONSE TRAJECTORIES, STUDY ENDPOINTS, AND MUCOSAL GENE TRANSCRIPTOMIC ANALYSES

Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel disease

S1815 Early Response to Vedolizumab in Patients With Crohn&#x27;s Disease in a Prospective Observational Study in Canada and US: The VOICE Study

S1924 Further Validation of the Vedolizumab Clinical Decision Support Tool to Predict the Likelihood of Clinical Remission in Vedolizumab-Treated Patients With Crohn’s Disease

Disease Clearance in Ulcerative Colitis: A Narrative Review

P62 Low rates of transition from subcutaneous to intravenous formulation in patients with inflammatory bowel diseases treated with vedolizumab

Su1992: MUCOSAL TRANSCRIPTOMIC ANALYSIS CONFIRMS CLINICAL RESPONSE TRAJECTORIES FOR VEDOLIZUMAB AND SHOWS NEW MOLECULAR INSIGHTS

Tu1815: LONG-TERM SAFETY OF SUBCUTANEOUS VEDOLIZUMAB IN ULCERATIVE COLITIS AND CROHN’S DISEASE: FINDINGS FROM THE VISIBLE OLE STUDY

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence

Sa1773 MACHINE LEARNING-BASED PRECISION MEDICINE APPROACH IDENTIFIES SPECIFIC RESPONDER SUB-POPULATIONS IN PATIENTS TREATED WITH VEDOLIZUMAB BY DYNAMIC CLUSTERING OF PRO-2 DATA: POST HOC ANALYSIS OF VARSITY AND CONFIRMATION IN THE GEMINI DATASET

Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay

P348 Disease trajectories in ulcerative colitis: Early identification of patients with endoscopic remission at Week 52

P354 Application of the clinical decision support tool to predict treatment outcomes in Crohn’s Disease patients treated with vedolizumab subcutaneous formulation

P703 Real world experience of the transition from the intravenous to subcutaneous formulation of vedolizumab in inflammatory bowel disease: A review of current data

S1170 Corticosteroid-Free Remission in Anti-TNF-Failed Crohn’s Disease Patients Treated With Vedolizumab as Second-Line Biologic Therapy: A Real World Data Review

S900 Response Trajectory by the Clinical Decision Support Tool Probability Groups in Vedolizumab-Treated Patients With Crohn’s Disease: A Pooled Analysis of GEMINI 2, VISIBLE 2, and VERSIFY

Sa1157 DISEASE TRAJECTORIES IN ULCERATIVE COLITIS: EARLY IDENTIFICATION OF PATIENTS WITH ENDOSCOPIC REMISSION AT WEEK 52

Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study

Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease

Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe

P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial

Su463 Vedolizumab Rates of Mucosal Healing in Crohn's Disease: A Systematic Literature Review And Meta-Analysis of Real-World Data

Collaborators (4)

Raja Atreya

Alessandro Armuzzi

Laurent Peyrin‐Biroulet

Shahnaz Khan

Make your next move.

S1815 Early Response to Vedolizumab in Patients With Crohn's Disease in a Prospective Observational Study in Canada and US: The VOICE Study